OTHER INFORMATION. 
+Added: On August 8, 2022, the Compensation Committee of the Company’s Board of Directors approved the payment of a cash bonus to Mr.
+Added: Walter Klemp of $375,000 payable upon the dosing of the first patient in the Company’s Phase 2 clinical trial of Annamycin for the treatment of soft tissue sarcoma lung metastases.
EXHIBITS 
−Removed: Patent and Technology License Agreement dated February 3, 2022, by and between The Board of Regents of The University of Texas System on behalf of The University of Texas M.D.
−Removed: Anderson Cancer Center and Moleculin Biotech, Inc.
−Removed: (incorporated by reference to Exhibit 10.34 of the Company’s 10-K filed March 24, 2022)
Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002
14 unchanged sentences
MOLECULIN BIOTECH, INC.
+Added: August 12, 2022
/s/ Walter V.
1 unchanged sentence
(Principal Executive Officer)
+Added: August 12, 2022
/s/ Jonathan P.
2 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.